Anti-lymphangiogenic action of SAHA on breast cancer
博士 === 國立中山大學 === 生物醫學研究所 === 101 === HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) exhibits anti-tumor effects on various types of human cancers and is now approved by U.S FDA for clinical cancer treatment. SAHA also suppresses tumor angiogenesis. However, the effect of SAHA on tumor lympha...
Main Authors: | Hsueh-Tsen Cheng, 鄭雪岑 |
---|---|
Other Authors: | Wen-Chun Hung |
Format: | Others |
Language: | en_US |
Published: |
2013
|
Online Access: | http://ndltd.ncl.edu.tw/handle/37812556370839855915 |
Similar Items
-
Lymphangiogenic Signaling in the Epicardium
by: Karunamuni, Ganga
Published: (2011) -
Vorinostat (SAHA) and Breast Cancer: An Overview
by: Anna Wawruszak, et al.
Published: (2021-09-01) -
Deciphering pro-lymphangiogenic programs during mammary involution and postpartum breast cancer
by: Virginia F Borges, et al.
Published: (2016-11-01) -
Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines.
by: Erin Regan, et al.
Published: (2016-01-01) -
Dynamic Expression of Angiogenic and Lymphangiogenic Factors in Breast Tumor-bearing Mice
by: Wei-ChungTseng, et al.
Published: (2010)